Galectin Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
GALT Nasdaq 2834 http://www.galectintherapeutics.com 2.73 Stock Down -0.14

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galectin Therapeutics Inc

Can The Uptrend Continue for Galectin Therapeutics (GALT)? - Sep 23rd, 2016 2:34 pm
5 Biotech Stocks to Watch as Interest in NASH Increases - Sep 22nd, 2016 1:08 pm
Is Galectin The Next Takeover Target for the Biotech World? - Sep 22nd, 2016 9:53 am
NASH Hype Has These 2 Stocks Soaring, Plus the Latest On MGT Capital, PTC Therapeutics, and Cloud Peak Energy - Sep 20th, 2016 5:02 pm
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference - Aug 31st, 2016 12:00 pm
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial - Aug 25th, 2016 12:08 pm
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial - Aug 25th, 2016 12:00 pm
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Aug 25th, 2016 11:52 am
GALECTIN THERAPEUTICS INC Financials - Aug 17th, 2016 5:04 pm
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update - Aug 9th, 2016 12:30 pm
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update - Aug 9th, 2016 12:00 pm
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and - Aug 9th, 2016 11:51 am
GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report - Aug 9th, 2016 11:43 am
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis - Aug 2nd, 2016 1:01 pm
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis - Aug 2nd, 2016 12:45 pm
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Aug 2nd, 2016 12:31 pm
Galectin Therapeutics (GALT) Jumps: Stock Rises 17.1% - Aug 2nd, 2016 12:25 pm
Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of Plant-Derived Complex Carbohydrates - Jul 13th, 2016 1:08 pm
Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of Plant-Derived Complex Carbohydrates - Jul 13th, 2016 12:56 pm
Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis - Jul 12th, 2016 1:03 pm